Skip to main content
. 2020 Apr 29;21(1):41. doi: 10.1186/s10194-020-01110-9

Fig. 3.

Fig. 3

Patient-reported outcomes in patients with migraine receiving treatment for acute migraine: a MIDAS; b MSQ; and c EQ-5D-5L scores according to response to triptan medication. Data were controlled for age, sex, migraine headache day frequency, comorbidities, duration of illness, preventive medication use, and presence of aura. *p < 0.001 for TIRs versus TRs using multivariable general linear model controlling for age, sex, migraine headache day frequency, comorbidities, duration of illness, preventive medication use, and migraine with or without aura. Note: Higher MIDAS score indicates greater disability; lower MSQ score indicates lower HRQoL; lower EQ-5D-5L score indicates lower HRQoL. EQ-5D-5L = EuroQol 5-Dimensions 5-Levels questionnaire; HRQoL = health-related quality of life; LS = least squares; MIDAS = Migraine Disability Assessment; MSQ = Migraine-Specific Quality of Life Questionnaire; SE = standard error; TIR = triptan insufficient responder; TR = triptan responder, VAS = visual analog scale